Cargando…
Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial
Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658579/ https://www.ncbi.nlm.nih.gov/pubmed/36364740 http://dx.doi.org/10.3390/nu14214470 |
_version_ | 1784829986185674752 |
---|---|
author | Abe, Tatsuya Koyama, Yukari Nishimura, Kosaku Okiura, Aya Takahashi, Toru |
author_facet | Abe, Tatsuya Koyama, Yukari Nishimura, Kosaku Okiura, Aya Takahashi, Toru |
author_sort | Abe, Tatsuya |
collection | PubMed |
description | Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (Ficus carica L.) leaves alleviated allergy and AD symptoms in cultured cells and animals. Therefore, here, we conducted a double-blind, randomized, controlled study in patients with mild AD to evaluate the safety and AD-relieving effects of prolonged consumption of fig leaf tea. Positive effects of fig leaf tea consumption were confirmed in 14 of 15 participants. Eczema Area and Severity Index values were significantly lowered in the fig leaf tea-treated group than in the placebo-treated group. The effect weakened 4 weeks after the end of the intervention, suggesting that continued intake of fig leaf tea was effective. Further assessments confirmed the safety of fig leaf tea consumption and revealed no variations that might pose a health hazard. Therefore, we postulate that fig leaf tea is a natural and safe therapeutic option for AD. |
format | Online Article Text |
id | pubmed-9658579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96585792022-11-15 Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial Abe, Tatsuya Koyama, Yukari Nishimura, Kosaku Okiura, Aya Takahashi, Toru Nutrients Article Atopic dermatitis (AD) is a chronic, recurrent pruritic skin disease with repeated remissions and exacerbations. Various factors, such as allergies, skin conditions and lifestyle, combine to cause AD, making it difficult to cure completely. Although AD symptoms are suppressed with medications, this is a long-term effort and burden on patients. Thus, safer drugs and alternatives are needed. We previously found that consumption of tea prepared from fig (Ficus carica L.) leaves alleviated allergy and AD symptoms in cultured cells and animals. Therefore, here, we conducted a double-blind, randomized, controlled study in patients with mild AD to evaluate the safety and AD-relieving effects of prolonged consumption of fig leaf tea. Positive effects of fig leaf tea consumption were confirmed in 14 of 15 participants. Eczema Area and Severity Index values were significantly lowered in the fig leaf tea-treated group than in the placebo-treated group. The effect weakened 4 weeks after the end of the intervention, suggesting that continued intake of fig leaf tea was effective. Further assessments confirmed the safety of fig leaf tea consumption and revealed no variations that might pose a health hazard. Therefore, we postulate that fig leaf tea is a natural and safe therapeutic option for AD. MDPI 2022-10-25 /pmc/articles/PMC9658579/ /pubmed/36364740 http://dx.doi.org/10.3390/nu14214470 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Abe, Tatsuya Koyama, Yukari Nishimura, Kosaku Okiura, Aya Takahashi, Toru Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title | Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title_full | Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title_fullStr | Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title_full_unstemmed | Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title_short | Efficacy and Safety of Fig (Ficus carica L.) Leaf Tea in Adults with Mild Atopic Dermatitis: A Double-Blind, Randomized, Placebo-Controlled Preliminary Trial |
title_sort | efficacy and safety of fig (ficus carica l.) leaf tea in adults with mild atopic dermatitis: a double-blind, randomized, placebo-controlled preliminary trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9658579/ https://www.ncbi.nlm.nih.gov/pubmed/36364740 http://dx.doi.org/10.3390/nu14214470 |
work_keys_str_mv | AT abetatsuya efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial AT koyamayukari efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial AT nishimurakosaku efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial AT okiuraaya efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial AT takahashitoru efficacyandsafetyoffigficuscaricalleafteainadultswithmildatopicdermatitisadoubleblindrandomizedplacebocontrolledpreliminarytrial |